NICE's first choice in ulcerative colitis is not infliximab
This article was originally published in Scrip
Acute exacerbations of severely active ulcerative colitis should be treated with infliximab (Schering-Plough's/Johnson & Johnson's Remicade) only if ciclosporin is contraindicated, says the UK's National Institute for health and Clinical Excellence(NICE) in draft guidance. If finalised in its present form, the guidance would prevent significant sales of the product in the national health service in England and Wales for this indication.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.